Novartis spruces up Sandoz—again—by bringing 6 new US generics into the fold

Novartis has been busy beefing up Sandoz on the way to spin out the unit into the world’s largest generics company.

In a new deal unveiled Thursday, Sandoz obtained exclusive rights to sell six small-molecule generic candidates in the U.S. from Malta-based pharmaceutical company Adalvo.